This is a plain-language guide to adult ADHD: what it is, why so many people reach their thirties or forties without a diagnosis, how a real evaluation works, what treatment does and does not do, and how any of this is accessed if you live in Washington State.
It is written by a physician assistant who works exclusively in adult ADHD care, and it tries to be honest about where the evidence is strong and where it is thinner than the internet suggests.
What Adult ADHD Actually Is
ADHD is a disorder of self-regulation. Not of intelligence, not of effort, and not of caring enough.
The functions it disrupts are the ones that let a person sustain attention on something unrewarding, start a task before it becomes urgent, hold information in mind while using it, judge how much time has passed, and modulate an emotional response before it takes over. Those functions depend heavily on prefrontal networks and on dopamine and norepinephrine signaling, which is why the medications that help are the ones acting on those systems.
In adults the presentation usually looks less like restlessness and more like a life that takes more effort to hold together than it seems like it should. Deadlines met at the last possible moment. A career that plateaued for reasons nobody could name. Piles of started projects. A sense of running on adrenaline because adrenaline is the only thing that reliably produces focus.
How Common Is It in Adults
A 2021 global systematic review and meta-analysis estimated that persistent adult ADHD, meaning symptoms that carry forward from childhood and still meet full criteria, affects roughly 2.6 percent of adults.1 Symptomatic adult ADHD, a broader category capturing clinically significant symptoms that may not meet every criterion, was estimated at about 6.8 percent.
Those two numbers are worth separating. The gap between them is where a great many adults live: impaired enough that it shapes their work and relationships, not always tidy enough to match a checklist written with children in mind.
Why So Many Adults Are Diagnosed Late
The most common reason ADHD gets missed in adults is that the person was managing, at a cost nobody could see.
Intelligence, anxiety, and external structure are all effective substitutes for executive function, right up until they are not. A 2025 study of 900 adults with ADHD found no significant difference between men and women in the age symptoms began, but women were diagnosed significantly later, and by the time they were diagnosed they had greater symptom severity, more depression and anxiety, and greater disability.2
That pattern shows up clinically as the person who graduated college and was told that ruled ADHD out, and as the woman whose emotional intensity was read as a personality trait rather than a symptom.
Diagnosis often follows a life transition that removes the scaffolding: a less structured job, a move, a baby, a loss. The symptoms were always there. The workarounds ran out.
What Gets Diagnosed Instead
The years before an ADHD diagnosis are rarely empty. They usually contain other diagnoses, and often those diagnoses are partly right.
Anxiety and depression are the most common, and both are genuinely present in many cases. Someone compensating for absent executive function with adrenaline will be anxious. Someone failing at things they are clearly capable of, without knowing why, will become depressed. Treating those is not an error. Treating them as the entire story is.
Two other confusions matter enough to name. Reactive mood shifts lasting hours get read as the mood episodes of bipolar disorder, which last days to weeks and do not track external triggers. The two conditions genuinely co-occur, and a 2021 meta-analysis across 71 studies found roughly one in thirteen adults with ADHD also meet criteria for bipolar disorder,3 so the goal of a careful evaluation is not to pick a winner but to work out what the history supports.
Separately, rigid checking and ordering behaviors get labeled OCD when they are sometimes compensation for a working memory the person cannot trust. The behavior looks identical from outside. The belief underneath it is different, and so is the treatment.
How Adult ADHD Is Diagnosed
There is no blood test and no brain scan that diagnoses ADHD. The diagnosis is clinical, and a competent evaluation has a few non-negotiable parts.
A developmental history comes first. ADHD is a neurodevelopmental condition, so symptoms must trace back to childhood even if nobody named them at the time. School reports, family recollection, and the person's own account of adolescence all carry weight.
Current symptoms are assessed across more than one setting, because impairment confined to a single stressful job is a different finding than impairment that follows someone everywhere.
The differential diagnosis does much of the real work: sleep disorders, thyroid dysfunction, depression, anxiety, substance use, and trauma can all produce inattention. Ruling them in or out is not a formality at the end. It is most of the evaluation.
Validated rating scales are used, and objective measures such as computerized testing can add information about attention and impulsivity. It is worth being clear about what that testing does: it contributes data to a clinical picture. It does not by itself diagnose ADHD or rule it out.
Telehealth ADHD Care Under Washington Law
Washington State treats a telehealth visit as carrying the same legal and clinical weight as an in person visit for establishing a provider relationship, diagnosing, and prescribing.
Stimulant medications can currently be prescribed by telehealth without a prior in person visit, following a thorough evaluation, with the same requirements that apply in person: full clinical assessment, verification through the Washington State Prescription Monitoring Program, and electronic prescribing.
The part most articles leave out is that the federal permission is temporary. The flexibilities allowing controlled substances to be prescribed by telemedicine without a prior in person exam began as a pandemic measure and have been extended four times. The current extension runs through December 31, 2026, and the permanent framework the DEA proposed in January 2025 has not been finalized.
What that means practically: telehealth stimulant prescribing is legal today, and the 2027 rules are not yet written. A reasonable question to ask any telehealth ADHD practice is what their plan is if the rules change, and whether they are comfortable with non-stimulant options, which controlled substance rules do not touch. There is more detail on how telehealth ADHD diagnosis works in a separate article.
What Treatment Actually Does
A 2018 network meta-analysis pooled 133 double-blind randomized trials across children, adolescents and adults.4 In adults, amphetamines, methylphenidate, bupropion and atomoxetine all outperformed placebo, with amphetamines ahead of the others on clinician ratings.
A 2025 component network meta-analysis looked specifically at adults, pooling 113 randomized trials and comparing pharmacological, psychological and neurostimulatory approaches.5 Stimulants and atomoxetine were the only interventions with evidence of benefit on core ADHD symptoms in the short term, and that held on both self-reported and clinician-reported ratings.
Two findings from that same analysis get quoted far less often, and they matter. ADHD medications did not show benefit on quality of life measures. And longer-term evidence was described as underinvestigated across every intervention studied.
So the honest summary: medication has the strongest short-term evidence for reducing core symptoms, nothing in this field has strong long-term evidence, and improvement in symptoms is not the same thing as improvement in life. That last gap is where the rest of treatment lives.
What Medication Does Not Do
Medication improves the neurological conditions that make effort possible. It does not install systems, undo twenty years of avoidance, or repair the beliefs someone formed about themselves while struggling with something nobody had named.
People often notice this first with task initiation. The internal activation improves, and the anxiety that accumulated around specific tasks does not automatically follow.
Sleep is the other common gap. Poor sleep degrades exactly the prefrontal functions ADHD already taxes, and it is one of the most frequent reasons a medication that was working seems to stop. Movement and mindfulness have real but modest evidence for ADHD symptoms specifically, and they earn their place partly through sleep and regulation rather than through symptom reduction alone.
Safety Questions People Actually Ask
Cardiovascular effects are the most common concern. A 2025 network meta-analysis of cardiovascular safety across ADHD medications found that most raise heart rate and blood pressure modestly, with guanfacine the exception in lowering both.6 That is a real effect worth monitoring, and it is a different claim from a serious cardiac event.
The risk that gets discussed least is the risk of leaving ADHD untreated. A 2017 study of more than 2.3 million people with ADHD found crash risk roughly 38 percent lower in men and 42 percent lower in women during months they were taking medication compared with their own unmedicated months.7 A 2025 series of target trial emulations found ADHD medication associated with reduced risk of suicidal behaviour, substance misuse, accidental injury, transport accidents and criminality.8
Both sides of that ledger belong in the conversation. There is more on the driving evidence, including a study that complicates it, in a separate article on ADHD and safety.
Why Treatment Quality Matters More Than Being On Treatment
One theme runs through all of the above. The benefit in the research comes from medication actually taken at an actually optimized dose, not from having a prescription on file.
This is why a medication that worked for months and then seemed to stop is not a neutral situation to leave alone. Sleep, stress, hormonal changes, timing and dosing all affect how a medication performs, and each has a different answer. An unexamined stretch on an ineffective dose is functionally an untreated stretch.
It also means the first medication tried is not a test of whether medication works. The agents are not interchangeable: they differ in mechanism, duration, side effect profile and cardiovascular effect, and a 2022 systematic review found no reliable biological marker that predicts which adult will respond to which drug.9 Since the answer cannot be predicted, it has to be found, which argues for comparing options deliberately rather than starting one and hoping. That reasoning is worked through in being on ADHD medication versus being on the right one.
Practically, that means the questions worth asking a prospective prescriber are about process: how often will we reassess, what will we measure, how many options are they prepared to try, and what happens if the first one does not work.
Getting Started in Washington State
Clarity ADHD is a telehealth psychiatry practice serving adults across Washington State, including Seattle, Tacoma, Spokane and Bellevue. Care is provided by Lucas Craft, MMS, PA-C, who is board certified by the NCCPA, Washington licensed, DEA registered, and practices in collaboration with a licensed physician in accordance with Washington State law.
The practice offers a structured six week evaluation and optimization program built around the follow-through problem described above, with three systematic medication trials rather than a single prescription, with transparent flat pricing and no insurance billing. It treats adult ADHD along with the conditions that commonly travel with it, and it does not provide therapy or crisis services.
Patients must be 18 or older and physically located in Washington State at the time of their appointment. All visits are by secure video.
If any of this describes your experience, the useful next step is not self-diagnosis from an article. It is an evaluation thorough enough to answer the question properly, including the possibility that the answer is something other than ADHD.
References
1. Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health. 2021;11:04009. doi:10.7189/jogh.11.04009
2. Mestres F, Richarte V, Crespin JJ, et al. Sex differences in adults with attention-deficit/hyperactivity disorder: a population-based study. European Psychiatry. 2025;68(1):e90. doi:10.1192/j.eurpsy.2025.2441
3. Schiweck C, Arteaga-Henriquez G, Aichholzer M, et al. Comorbidity of ADHD and adult bipolar disorder: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 2021;124:100 to 123. doi:10.1016/j.neubiorev.2021.01.017
4. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727 to 738. doi:10.1016/S2215-0366(18)30269-4
5. Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. 2025;12(1):32 to 43. doi:10.1016/S2215-0366(24)00360-2
6. Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2025;12(5):355 to 365. doi:10.1016/S2215-0366(25)00062-8
7. Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74(6):597 to 603. doi:10.1001/jamapsychiatry.2017.0659
8. Zhang L, Zhu N, Sjolander A, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. 2025;390:e083658. doi:10.1136/bmj-2024-083658
9. Capuzzi E, Caldiroli A, Auxilia AM, Borgonovo R, Capellazzi M, Clerici M, Buoli M. Biological predictors of treatment response in adult attention deficit hyperactivity disorder (ADHD): a systematic review. Journal of Personalized Medicine. 2022;12(10):1742. doi:10.3390/jpm12101742
Clarity ADHD is a telehealth psychiatry practice in Washington State offering adult ADHD evaluation and medication management, including care for co-occurring depression and anxiety. Now accepting new patients, and you can start with a free 15-minute consultation to see if it is a fit.
Book a Free 15-Minute ConsultationThe content on this website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.